Beta Drugs Limited (NSE:BETA)

India flag India · Delayed Price · Currency is INR
1,141.80
-231.80 (-16.88%)
Last updated: Feb 16, 2026, 2:16 PM IST
Market Cap13.87B -18.3%
Revenue (ttm)3.86B +15.2%
Net Income418.99M +2.2%
EPS53.63 +32.0%
Shares Out10.09M
PE Ratio25.61
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume70,890
Average Volume7,856
Open1,290.60
Previous Close1,373.60
Day's Range1,114.10 - 1,302.00
52-Week Range1,127.00 - 2,000.00
Beta-0.36
RSI22.81
Earnings DateFeb 12, 2026

About Beta Drugs

Beta Drugs Limited develops, manufactures, and sells anti-cancer bulk drugs and finished dosages in India. The company offers cosmeceutical and oncology products. It also manufactures active pharmaceutical ingredients (API) and pharmaceutical formulation intermediates (PFI). The company exports its products. Beta Drugs Limited was founded in 1985 and is based in Panchkula, India. [Read more]

Sector Healthcare
Founded 1985
Employees 399
Stock Exchange National Stock Exchange of India
Ticker Symbol BETA
Full Company Profile

Financial Performance

In fiscal year 2025, Beta Drugs's revenue was 3.62 billion, an increase of 22.54% compared to the previous year's 2.96 billion. Earnings were 424.19 million, an increase of 16.42%.

Financial Statements